A comprehensive review of adherence to diabetes and cardiovascular medications in Iran; implications for practice and research

Journal of Diabetes & Metabolic Disorders

Kheirollah Gholami²  Mohammadreza Javadi²  Alireza Ahmadvand¹  Molouk Hadjibabaie²  Zahra Jahangard-Rafsanjani²  Amir Sarayani³ 

[1] School of Public Health, Tehran University of Medical Sciences, Tehran, Iran;Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran;Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran

关键词: Iran;    Patient education;    Oral hypoglycemic medications;    Diabetes mellitus;    Hypertension;    Cardiovascular diseases;    Patient compliance;    Medication adherence;   

Others  :  806688
DOI  :  10.1186/2251-6581-12-57

 received in 2013-05-15, accepted in 2013-10-06,  发布年份 2013

【 摘 要 】

Treatment of diseases such as diabetes mellitus and cardiovascular disorders are highly dependent on medications and particularly adherence to medications to achieve optimal pharmacotherapy outcomes. Several factors can affect a patient’s adherence including: knowledge and beliefs about their illness and medications, concomitant psychological disorders, type of therapeutic regimen, and lack of access to medicines. In Iran, a middle income country, essential medicines are highly available and affordable. However, adherence to medications has not been emphasized especially for patients with diabetes and cardiovascular diseases. In the present study, we reviewed the available literature on adherence to medications used to treat diabetes and cardiovascular disorders in Iran. We systematically searched Scopus, Web of Science, PubMed, CINAHL, Google Scholar, Scientific Information Database, and IranMedex using a highly sensitive protocol on July 2012. We retrieved 1003 citations; and two independent researchers screened them for relevant publications. Studies were included if they reported rate or determinants of adherence to diabetes mellitus and cardiovascular medications. Trials on improving interventions were also included. The quality of studies was assessed using appropriate guidelines. Fourteen studies were eligible for data extraction and review. The definition of adherence and the measurement tools used were unclear among studies. Methodological caveats including inappropriate sample size, sampling methods, inclusion/exclusion criteria, and high rate of loss to follow-up were also observed. Nevertheless, adherence rate was reported to be 62.8-86.3% for oral hypoglycemic medications and 38.8-60.0% for cardiovascular medicines. Forgetfulness, lack of knowledge about medical condition and prescribed medications, and concerns about medications efficacy and side effects were consistently reported as barriers to adherence. Patient education plus telephone or short message service follow-ups were reported to improve adherence to oral hypo-glycemic medications. We did not find any high quality trials on adherence to cardiovascular medicines. In conclusion, adherence to cardiovascular and diabetes medications is not assured in Iranian patients. Based on the available literature, patient education and reinforcement interventions are required to address this issue. Future studies should employ careful designs and standard tools for assessment of adherence to medications.

【 授权许可】

   
2013 Sarayani et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK: Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
• [2]Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005, 353:487-497.
• [3]Brown MT, Bussell JK: Medication adherence: WHO Cares? Mayo Clin Proc 2011, 86:304-314.
• [4]Bangsberg DR: Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006, 43:939-941.
• [5]Kobin AB, Sheth NU: Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother 2011, 45:372-379.
• [6]Rasmussen JN, Chong A, Alter DA: Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297:177-186.
• [7]Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA: A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006, 333:15.
• [8]Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M: Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009, 12:915-922.
• [9]Cramer JA: A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:1218-1224.
• [10]Baroletti S, Dell’Orfano H: Medication adherence in cardiovascular disease. Circulation 2010, 121:1455-1458.
• [11]Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR: Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J 2009, 15:591-599.
• [12]Javanbakht M, Baradaran HR, Mashayekhi A, Haghdoost AA, Khamseh ME, Kharazmi E, Sadeghi A: Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS One 2011, 6:e26864.
• [13]Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi S, Mahdavi Hezaveh N, Kazemeini H: The burden of disease and injury in Iran 2003. Popul Health Metr 2009, 7:9. BioMed Central Full Text
• [14]Sadeghi M, Roohafza HR, Kelishadi R: Blood pressure and associated cardiovascular risk factors in Iran: Isfahan Healthy Heart Programme. Med J Malaysia 2004, 59:460-467.
• [15]Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M: Adherence to glyburide and metformin and associated factors in type 2 diabetes in Isfahan, Iran. Iran J Pharm Res 2011, 10:933-939.
• [16]Hadi N, Rostami-Gooran N: Determinant factors of medication compliance in hypertensive patients of Shiraz, Iran. Arch Iran Med 2004, 7:292-296.
• [17]Gellad WF, Grenard J, McGlynn EA: A Review of Barriers to Medication Adherence: A Framework for Driving Policy Options. Santa Monica, CA: RAND Corporation; 2009. http://www.rand.org/pubs/technical_reports/TR765 webcite
• [18]Lehane E, McCarthy G: Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007, 44:1468-1477.
• [19]Krueger KP, Berger BA, Felkey B: Medication adherence and persistence: a comprehensive review. Adv Ther 2005, 22:313-356.
• [20]Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008. Issue 2. Art. No.: CD000011. DOI: 10.1002/14651858.CD000011.pub3
• [21]Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK: A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med 2011, 26:1479-1491.
• [22]Cheraghali AM, Nikfar S, Behmanesh Y, Rahimi V, Habibipour F, Tirdad R, Asadi A, Bahrami A: Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran. East Mediterr Health J 2004, 10:406-415.
• [23]Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4:e297.
• [24]Critical Appraisal Skills Programme(CASP) Checklist; making sense of evidence Solut Public Health, NHShttp://www.casp-uk.net/find-appraise-act/appraising-the-evidence/ webcite
• [25]Parsa-Yekta Z, Moghaddam Z, Mehran A, Palizdar M: Study of medication compliance of patients with coronary heart diseases and associated factors [Farsi]. HAYAT 2004, 9:34-44.
• [26]Dabaghian H, Karbakhsh-davari M, Soheilikhah S, Sedaghat M: [Adherence to medications in type 2 diabetic patients in Shariati and imam Khomeini hospitals] (Fa). Payesh 2005, 4:111-103.
• [27]Zolfaghari M, Mousavifar SA, Pedram S, Haghani H: The impact of nurse short message services and telephone follow-ups on diabetic adherence: which one is more effective? J Clin Nurs 2012, 21:1922-1931.
• [28]Nesari M, Zakerimoghadam M, Rajab A, Bassampour S, Faghihzadeh S: Effect of telephone follow-up on adherence to a diabetes therapeutic regimen. Jpn J Nurs Sci 2010, 7:121-128.
• [29]Heydari A, Ahrari S, Vaghee S: The relationship between self-concept and adherence to therapeutic regimens in patients with heart failure. J Cardiovasc Nurs 2011, 26:475-480.
• [30]Hadi N, Rostami-Gooran N: Effectiveness of a hypertension educational program on increasing medication compliance in Shiraz, 2004. Shiraz E Medical J 2006, 7:1-6.
• [31]Aflakseir A: The role of illness and medication perceptions on adherence to medicines in a group of Iranian patients with type 2 diabetes. J Diabetes 2012, 4:243-247. doi: 10.1111/j.1753-0407.2012.00183.x
• [32]Abbasi M, Salemi S, Fatemi NS, Hosseini F: Hypertensive patients, their compliance level and its relation to their health beliefs. Iran J Nurs 2005, 18:61-68.
• [33]Alizad-jahani S, Majdzadeh R, Ghorbani M, Khosravi S, Bajoori A, Larijani M: [Evaluation of factors underlying non-adherence to insulin therapy in Iranian diabetic patients 2010–2011; a qualitative study] (Fa). Majalleh Diabet va Lipid Iran 2011, 10:520-527.
• [34]Mohammadi E, Abedi HA, Gofranipour F, Jalali F: Partnership caring: a theory of high blood pressure control in Iranian hypertensives. Int J Nurs Pract 2002, 8:324-329.
• [35]Heydari A, Ziaee ES, Ebrahimzadeh S: The frequency of rehospitalization and its contributing factors in patients with cardiovascular diseases hospitalized in selected hospitals in Mashhad in 2010. Ofogh-e-Danesh; J Gonabad Univ Med Sci 2011, 17:65-71.
• [36]Mohamadi M, Dadkhah B, Sezavar S-H, Mozafari N: Impact of follow-up program on control of high blood pressure in hypertensive patients. J Ardabil Univ Med Sci 2006, 6:156-162.
• [37]DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW: Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002, 40:794-811.
• [38]Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008, 155:772-779.
• [39]Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ: Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006, 166:1836-1841.
• [40]Yang Y, Thumula V, Pace PF, Banahan BF 3rd, Wilkin NE, Lobb WB: Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther 2009, 31:2178-2188. discussion 2150–2171
• [41]Gellad WF, Grenard JL, Marcum ZA: A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 2011, 9:11-23.
• [42]Andrade AS, McGruder HF, Wu AW, Celano SA, Skolasky RL Jr, Selnes OA, Huang IC, McArthur JC: A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis 2005, 41:875-882.
• [43]Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ: Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005, 6:185-190.
• [44]Schedlbauer A, Davies P, Fahey T: Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010. Issue 3. Art. No.: CD004371. DOI: 10.1002/14651858.CD004371.pub3
• [45]Schroeder K, Fahey T, Ebrahim S: Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004. Issue 3. Art. No.: CD004804. DOI: 10.1002/14651858.CD004804
• [46]Gwadry-Sridhar FH, Manias E, Zhang Y, Roy A, Yu-Isenberg K, Hughes DA, Nichol MB: A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther 2009, 31:421-435.
• [47]Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS Jr: Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol 2011, 64:250-254.
• [48]Garfield S, Clifford S, Eliasson L, Barber N, Willson A: Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol 2011, 11:149. BioMed Central Full Text